Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given an average rating of “Buy” by the sixteen ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $32.6364.

A number of analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price target on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a report on Monday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a research report on Monday, November 17th. Finally, Morgan Stanley cut their price target on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, August 18th.

Denali Therapeutics Trading Up 1.5%

Shares of NASDAQ:DNLI opened at $19.69 on Monday. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $26.18. The company’s 50 day moving average is $16.13 and its two-hundred day moving average is $14.96. The company has a market cap of $2.89 billion, a PE ratio of -6.76 and a beta of 1.11. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. The business’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.63) EPS. Equities analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Denali Therapeutics in the 2nd quarter valued at about $55,224,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Denali Therapeutics by 88.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock valued at $91,996,000 after buying an additional 3,184,042 shares during the last quarter. Holocene Advisors LP lifted its stake in Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after buying an additional 2,732,540 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Denali Therapeutics by 15.9% in the first quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company’s stock valued at $155,113,000 after acquiring an additional 1,561,647 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Denali Therapeutics by 42.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company’s stock worth $59,373,000 after acquiring an additional 1,308,619 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.